Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2014

01-04-2014 | Epidemiology

Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history

Authors: Peter Choon Eng Kang, Sze Yee Phuah, Kavitta Sivanandan, In Nee Kang, Eswary Thirthagiri, Jian Jun Liu, Norhashimah Hassan, Sook-Yee Yoon, Meow Keong Thong, Miao Hui, Mikael Hartman, Cheng Har Yip, Nur Aishah Mohd Taib, Soo Hwang Teo

Published in: Breast Cancer Research and Treatment | Issue 3/2014

Login to get access

Abstract

Although the breast cancer predisposition genes BRCA1 and BRCA2 were discovered more than 20 years ago, there remains a gap in the availability of genetic counselling and genetic testing in Asian countries because of cost, access and inaccurate reporting of family history of cancer. In order to improve access to testing, we developed a rapid test for recurrent mutations in our Asian populations. In this study, we designed a genotyping assay with 55 BRCA1 and 44 BRCA2 mutations previously identified in Asian studies, and validated this assay in 267 individuals who had previously been tested by full sequencing. We tested the prevalence of these mutations in additional breast cancer cases. Using this genotyping approach, we analysed recurrent mutations in 533 Malaysian breast cancer cases with <10 % a priori risk, and found 1 BRCA1 (0.2 %) and 5 BRCA2 (0.9 %) carriers. Testing in a hospital-based unselected cohort of 532 Singaporean breast cancer cases revealed 6 BRCA1 (1.1 %) and 3 BRCA2 (0.6 %) carriers. Overall, 2 recurrent BRCA1 and 1 BRCA2 mutations in Malays, 3 BRCA1 and 2 BRCA2 mutations in Chinese and 1 BRCA1 mutation in Indians account for 60, 24 and 20 % of carrier families, respectively. By contrast, haplotype analyses suggest that a recurrent BRCA2 mutation (c.262_263delCT) found in 5 unrelated Malay families has at least 3 distinct haplotypes. Taken together, our data suggests that panel testing may help to identify carriers, particularly Asian BRCA2 carriers, who do not present with a priori strong family history characteristics.
Appendix
Available only for authorised users
Literature
1.
go back to reference Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedCentralPubMed Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedCentralPubMed
3.
go back to reference Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, and Fu R (2013) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. preventive services task force recommendation. Ann Intern Med. doi:10.7326/M13-1684 Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, and Fu R (2013) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. preventive services task force recommendation. Ann Intern Med. doi:10.​7326/​M13-1684
4.
go back to reference Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN, National Comprehensive Cancer, N (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8(5):562–594PubMed Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN, National Comprehensive Cancer, N (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8(5):562–594PubMed
5.
go back to reference Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BB, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, Ford JM (2008) Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol 26(29):4752–4758CrossRefPubMedCentralPubMed Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BB, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, Ford JM (2008) Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol 26(29):4752–4758CrossRefPubMedCentralPubMed
6.
go back to reference Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, Yoon SY, Taib NA, Thong MK, Yip CH, Teo SH (2008) Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 10(4):R59CrossRefPubMedCentralPubMed Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, Yoon SY, Taib NA, Thong MK, Yip CH, Teo SH (2008) Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 10(4):R59CrossRefPubMedCentralPubMed
7.
go back to reference Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244CrossRefPubMed Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244CrossRefPubMed
8.
go back to reference Janavicius R (2010) Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1(3):397–412CrossRefPubMedCentralPubMed Janavicius R (2010) Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1(3):397–412CrossRefPubMedCentralPubMed
9.
go back to reference Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2(11):1179–1183CrossRefPubMed Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2(11):1179–1183CrossRefPubMed
10.
go back to reference Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aube J, Hanna D, Narod SA (2002) A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 20(5):352–357CrossRefPubMed Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aube J, Hanna D, Narod SA (2002) A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 20(5):352–357CrossRefPubMed
11.
go back to reference Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, Hocevar M, De Greve J (2008) Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 9:83CrossRefPubMedCentralPubMed Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, Hocevar M, De Greve J (2008) Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 9:83CrossRefPubMedCentralPubMed
12.
go back to reference van Der Looij M, Wysocka B, Brozek I, Jassem J, Limon J, Olah E (2000) Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Hum Mutat 15(5):480–481CrossRef van Der Looij M, Wysocka B, Brozek I, Jassem J, Limon J, Olah E (2000) Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Hum Mutat 15(5):480–481CrossRef
13.
go back to reference Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska L, Haus O, Janiszewska H, Niepsuj S, Gozdz S, Zaremba L, Posmyk M, Pluzanska M, Kilar E, Czudowska D, Wasko B, Miturski R, Kowalczyk JR, Urbanski K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Toloczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojc B, Mierzejewski M, Narod SA, Lubinski J (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110(5):683–686CrossRefPubMed Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska L, Haus O, Janiszewska H, Niepsuj S, Gozdz S, Zaremba L, Posmyk M, Pluzanska M, Kilar E, Czudowska D, Wasko B, Miturski R, Kowalczyk JR, Urbanski K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Toloczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojc B, Mierzejewski M, Narod SA, Lubinski J (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110(5):683–686CrossRefPubMed
14.
go back to reference Bergman A, Einbeigi Z, Olofsson U, Taib Z, Wallgren A, Karlsson P, Wahlstrom J, Martinsson T, Nordling M (2001) The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 9(10):787–793CrossRefPubMed Bergman A, Einbeigi Z, Olofsson U, Taib Z, Wallgren A, Karlsson P, Wahlstrom J, Martinsson T, Nordling M (2001) The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 9(10):787–793CrossRefPubMed
15.
go back to reference Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, McGuire C, Neuhausen S (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomark Prev 14(7):1666–1671CrossRef Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, McGuire C, Neuhausen S (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomark Prev 14(7):1666–1671CrossRef
16.
go back to reference Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamann U (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103(2):225–232CrossRefPubMed Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamann U (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103(2):225–232CrossRefPubMed
17.
go back to reference Malaysia, D.o.S. (2013) Statistics yearbook Malaysia 2012. Department of Statistics, Malaysia Malaysia, D.o.S. (2013) Statistics yearbook Malaysia 2012. Department of Statistics, Malaysia
18.
go back to reference S.D.o. Statistics (ed) (2013) Yearbook of statistics Singapore 2013. Singapore Department of Statistics, Singapore S.D.o. Statistics (ed) (2013) Yearbook of statistics Singapore 2013. Singapore Department of Statistics, Singapore
19.
go back to reference Kang P, Mariapun S, Phuah SY, Lim LS, Liu J, Yoon SY, Thong MK, Mohd Taib NA, Yip CH, Teo SH (2010) Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families. Breast Cancer Res Treat 124(2):579–584CrossRefPubMed Kang P, Mariapun S, Phuah SY, Lim LS, Liu J, Yoon SY, Thong MK, Mohd Taib NA, Yip CH, Teo SH (2010) Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families. Breast Cancer Res Treat 124(2):579–584CrossRefPubMed
20.
go back to reference Phuah SY, Lee SY, Kang P, Kang IN, Yoon SY, Thong MK, Hartman M, Sng JH, Yip CH, Taib NA, Teo SH (2013) Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore. PLoS ONE 8(8):e73638CrossRefPubMedCentralPubMed Phuah SY, Lee SY, Kang P, Kang IN, Yoon SY, Thong MK, Hartman M, Sng JH, Yip CH, Taib NA, Teo SH (2013) Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore. PLoS ONE 8(8):e73638CrossRefPubMedCentralPubMed
21.
go back to reference Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Ho LS, Kwan KH, Poon M, Wong TT, Leung FC, Chan SW, Ying MW, Ma ES, Ford JM (2009) A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat 117(3):683–686CrossRefPubMed Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Ho LS, Kwan KH, Poon M, Wong TT, Leung FC, Chan SW, Ying MW, Ma ES, Ford JM (2009) A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat 117(3):683–686CrossRefPubMed
22.
go back to reference Sng JH, Ali AB, Lee SC, Zahar D, Wong JE, Blake V, Sharif A, Cross G, Iau PT (2003) BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer. J Med Genet 40(10):e117CrossRefPubMedCentralPubMed Sng JH, Ali AB, Lee SC, Zahar D, Wong JE, Blake V, Sharif A, Cross G, Iau PT (2003) BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer. J Med Genet 40(10):e117CrossRefPubMedCentralPubMed
23.
go back to reference Balraj P, Khoo AS, Volpi L, Tan JA, Nair S, Abdullah H (2002) Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients. Singapore Med J 43(4):194–197PubMed Balraj P, Khoo AS, Volpi L, Tan JA, Nair S, Abdullah H (2002) Mutation analysis of the BRCA1 gene in Malaysian breast cancer patients. Singapore Med J 43(4):194–197PubMed
24.
go back to reference Tang NL, Pang CP, Yeo W, Choy KW, Lam PK, Suen M, Law LK, King WW, Johnson P, Hjelm M (1999) Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. J Natl Cancer Inst 91(10):882–885CrossRefPubMed Tang NL, Pang CP, Yeo W, Choy KW, Lam PK, Suen M, Law LK, King WW, Johnson P, Hjelm M (1999) Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. J Natl Cancer Inst 91(10):882–885CrossRefPubMed
25.
go back to reference Hu Z, Li WF, Liu XY, Zhang B, Cao MZ, Wang YS, Zhao L, Song CG, Lu JS, Wu J, Di GH, Shen KW, Han QX, Shen ZZ, Huang W, Shao ZM (2007) 5589del8: the recurrent mutation of BRCA1 gene in Chinese breast cancer patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24(4):378–381PubMed Hu Z, Li WF, Liu XY, Zhang B, Cao MZ, Wang YS, Zhao L, Song CG, Lu JS, Wu J, Di GH, Shen KW, Han QX, Shen ZZ, Huang W, Shao ZM (2007) 5589del8: the recurrent mutation of BRCA1 gene in Chinese breast cancer patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24(4):378–381PubMed
26.
go back to reference Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ, Su FX, Wang YS, He PQ, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Liu XY, Zhou J, Wang L, Zhao L, Liu YB, Yuan WT, Yang L, Shen ZZ, Huang W, Shao ZM (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110(1):99–109CrossRefPubMed Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ, Su FX, Wang YS, He PQ, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Liu XY, Zhou J, Wang L, Zhao L, Liu YB, Yuan WT, Yang L, Shen ZZ, Huang W, Shao ZM (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110(1):99–109CrossRefPubMed
27.
go back to reference Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES (2012) Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS ONE 7(9):e43994CrossRefPubMedCentralPubMed Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES (2012) Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS ONE 7(9):e43994CrossRefPubMedCentralPubMed
28.
go back to reference Saxena S, Chakraborty A, Kaushal M, Kotwal S, Bhatanager D, Mohil RS, Chintamani C, Aggarwal AK, Sharma VK, Sharma PC, Lenoir G, Goldgar DE, Szabo CI (2006) Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet 7:75CrossRefPubMedCentralPubMed Saxena S, Chakraborty A, Kaushal M, Kotwal S, Bhatanager D, Mohil RS, Chintamani C, Aggarwal AK, Sharma VK, Sharma PC, Lenoir G, Goldgar DE, Szabo CI (2006) Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet 7:75CrossRefPubMedCentralPubMed
29.
go back to reference Laitman Y, Feng BJ, Zamir IM, Weitzel JN, Duncan P, Port D, Thirthagiri E, Teo SH, Evans G, Latif A, Newman WG, Gershoni-Baruch R, Zidan J, Shimon-Paluch S, Goldgar D, Friedman E (2013) Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet 21(2):212–216CrossRefPubMedCentralPubMed Laitman Y, Feng BJ, Zamir IM, Weitzel JN, Duncan P, Port D, Thirthagiri E, Teo SH, Evans G, Latif A, Newman WG, Gershoni-Baruch R, Zidan J, Shimon-Paluch S, Goldgar D, Friedman E (2013) Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet 21(2):212–216CrossRefPubMedCentralPubMed
Metadata
Title
Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history
Authors
Peter Choon Eng Kang
Sze Yee Phuah
Kavitta Sivanandan
In Nee Kang
Eswary Thirthagiri
Jian Jun Liu
Norhashimah Hassan
Sook-Yee Yoon
Meow Keong Thong
Miao Hui
Mikael Hartman
Cheng Har Yip
Nur Aishah Mohd Taib
Soo Hwang Teo
Publication date
01-04-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-2894-x

Other articles of this Issue 3/2014

Breast Cancer Research and Treatment 3/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine